CDH11 and rheumatoid arthritis: As CDH11 antibody based therapeutics are in clinical trials for RA and we showed recently that the arthritis drug celecoxib has the structural potential to bind CDH11, there is a strong possibility that, if CDH11 can be shown to drive malignant progression rather than simply be associated with it, therapeutic options may be rapidly developed [7].